Clinical trials: Clostridium
Clostridium Difficile Infection
A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose exploration cohorts.
- Trial name
- NCT07649096
- Testing
- FZ002
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection, Recurrent Infection
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year.
- Trial name
- LIVEDIFF (NCT06306014)
- Testing
- EXL01
- Where
- 10 sites in France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Faecal microbiota transplantation (FMT) is used for Clostridioides difficile infection (CDI) as part of an quality improvement initiative and conducted within the framework of Center for Faecal Microbiota Transplantation at…
- Trial name
- CEFTA (NCT03712722)
- Testing
- Faecal microbiota transplantation (FMT)
- Where
- Denmark
- Volunteers
- 2,000 people
- Sponsor
- University of Aarhus
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection
Clostridioides difficile (CD) infection (CDI) is a global health threat with an urgent need for new treatment strategies. Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection…
- Trial name
- EarlyFMT (NCT04885946)
- Testing
- Fecal microbiota transplantion (FMT)
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Christian Lodberg Hvas
Clostridium Difficile Infection Recurrence
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Single-arm trial to evaluate the safety and efficacy of ACX-362E [ibezapolstat] in patients with recurrent C. difficile infection (CDI).
- Trial name
- NCT07513285
- Testing
- Ibezapolstat
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Acurx Pharmaceuticals Inc.
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile
Animal-Assisted Visitation Program Chlorhexidine Trial
Hospital-based Animal-Assisted visitation programs are important complementary therapies, but concerns with infection control may challenge the sustainability of these programs.
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
- Trial name
- NCT04171817
- Testing
- Chlorhexidine
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Clostridioides Difficile Infection
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response…
- Trial name
- Ri-CoDIFy 1 (NCT03595553)
- Testing
- Ridinilazole, Vancomycin
- Where
- 149 sites in United States, Argentina and 12 more
- Volunteers
- 759 people
- Sponsor
- Summit Therapeutics
Dysbiosis, Clostridium Difficile
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a disease associated with high morbidity and mortality, particularly among the elderly.
- Conditions
- Dysbiosis, Clostridium Difficile, Pet-Human Bonding, Antibiotic-Associated Colitis
- Trial name
- NCT05622721
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pennsylvania
Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
- Trial name
- PRISM (NCT07285213)
- Testing
- AZD5148
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Clostridioides Difficile Infection
LMN-201 for Prevention of C. Difficile Infection Recurrence
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
- Trial name
- NCT05330182
- Testing
- LMN-201
- Where
- 15 sites in United States
- Volunteers
- 375 people
- Sponsor
- Lumen Bioscience, Inc.
Clostridium Difficile, Clostridium Difficile Infections
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
- Trial name
- RESTORATiVE303 (NCT06237452)
- Testing
- VE303
- Where
- 215 sites in United States, Australia and 22 more
- Volunteers
- 852 people
- Sponsor
- Vedanta Biosciences, Inc.
Clostridium Difficile Infection, Health Care Associated Infection
Natural History of Clostridioides Difficile Infection
Aim: To investigate if host factors, such as composition and diversity of intestinal microbiota and/or genetic determinants, are associated with a higher risk of recurrence of Clostridioides difficile infection (CDI).
- Conditions
- Clostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection
- Trial name
- NCT04801862
- Where
- 15 sites in Spain
- Volunteers
- 750 people
- Sponsor
- Hospital Universitario de Valme
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection
This is a single-center, open-label study for safety and feasibility of IMT in patients undergoing colonic surgery. After consent, individuals of the ages of 18-75 with a history of diverticulitis or sigmoid colon cancer will be…
- Trial name
- NCT06370884
- Testing
- IMT
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Recurrent Clostridioides Difficile Infection, Colonic Surgery
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection
This Phase 1 pilot clinical trial that will evaluate the initial safety and feasibility of orally administered preparation of fecal microbiota (MTP-101P) in patients undergoing colon resection.
- Trial name
- NCT06692179
- Testing
- Orally administered preparation of fecal microbiota (MTP-101P)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Minnesota
Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA)
A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization
Multidrug-resistant organisms (MDROs) cause serious infections that are difficult to treat, leading to increased morbidity and mortality, longer hospital stays, and increased healthcare costs.
- Conditions
- Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae
- Trial name
- MDRO-Fiber (NCT07792915)
- Testing
- Resistant Potato Starch, Maltodextrin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- VA Office of Research and Development
Clostridium Difficile Colitis
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
It has been shown that restoration of the normal makeup of the bowel bacterial population is the most effective way to treat recurrent colitis due to Clostridium difficile.
- Trial name
- NCT02127398
- Testing
- fecal microbiota
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Duke University
Clostridium, Difficile
Optimal Treatment for Recurrent Clostridium Difficile
The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile…
- Conditions
- Clostridium, Difficile, Fidaxomicin, Vancomycin
- Trial name
- OpTION (NCT02667418)
- Testing
- Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 308 people
- Sponsor
- VA Office of Research and Development
Clostridium Difficile Infections
Safety Registry of a Fecal Microbiota Transplant Cohort
Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. Recurrent forms are a major problem with this infection.
- Trial name
- COSMIC-FMT (NCT06311006)
- Where
- France
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris